Descovy (Emtricitabine/Tenofov Alafenam) Patent Expiration, LOE Window & CMS Spending
Descovy (Emtricitabine/Tenofov Alafenam) by Gilead Sciences: FDA Orange Book core substance LOE 2033-02-15 (last listed 2036-06-29), 2 AB generics, $1.02B 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N208215 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2033-02-15 |
| Last Listed Patent or Exclusivity Date | 2036-06-29 |
| Orange Book Patents (*PED Extensions) | 8 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $1.02B |
| 2024 Medicare Part D Spend | $544.7M |
| 2024 Medicaid Spend | $470.3M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 17.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.